WebNov 20, 2024 · Background The prognosis for relapsed or refractory acute myeloid leukemia (RR-AML) in children is poor, and the preferred salvage chemotherapy is unclear. One regimen is cladribine, cytarabine, and granulocyte-colony stimulating factor (CLAG), but little is known about its efficacy and safety in children with RR-AML. Methods We … Webpediatric relapsed AML, although numbers were small. Fludarabine, cytarabine, and granulocyte colony-stimulating factor (FLAG) is a well-known reinduction regimen in AML.16,17 Because there is no evidence that anthracyclines improve survival from relapsed AML, whereas there is evidence that higher cumulative doses of …
FLAG (chemotherapy) - Wikipedia
WebBackground: The prognosis of children with acute myeloid leukemia (AML) has improved with the efficacy of hematopoietic cell transplantation (HCT) as a second-line therapy and improvements in supportive care following anthracycline- and cytarabine-based chemotherapy; however, the outcomes of children with relapsed AML still remain … WebFeb 14, 2013 · For example, in patients undergoing reinduction therapy, one of the most important factors predictive of reinduction success is the length of the CR1; the 1-year OS for the relapse-free interval from first CR of ≤ 6 months is 14%, 7-18 months is 36%, and > 18 months is 57%. 15 For patients with ALL, often the same induction chemotherapy … ordering catheter supplies
A review of treatment options employed in relapsed/refractory AML
WebBackground: According to the results of the international study Relapsed AML 2001/01 response was better after re-induction with L-DNR/FLAG (liposomal daunorubicin, … WebDec 16, 2024 · With advances in allogeneic hematopoietic stem cell transplant (allo-HCT), disease relapse has replaced transplant-related mortality as the primary cause of … WebNov 5, 2024 · In select older adults (e.g., those with good-risk cytogenetic/molecular abnormalities, or requiring reinduction for persistent AML), the risk/benefit for HiDAC may favor its use. Real world evidence is lacking on the safety of full dose HiDAC (total 18 grams/cycle) in fit older adults in the 60-75 age range. Methods irene r ritcher ct